Search Results - "Parker, C.C"

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial by Clarke, N.W., Ali, A., Ingleby, F.C., Hoyle, A., Amos, C.L., Attard, G., Brawley, C.D., Calvert, J., Chowdhury, S., Cook, A., Cross, W., Dearnaley, D.P., Douis, H., Gilbert, D., Gillessen, S., Jones, R.J., Langley, R.E., MacNair, A., Malik, Z., Mason, M.D., Matheson, D., Millman, R., Parker, C.C., Ritchie, A.W.S., Rush, H., Russell, J.M., Brown, J., Beesley, S., Birtle, A., Capaldi, L., Gale, J., Gibbs, S., Lydon, A., Nikapota, A., Omlin, A., O'Sullivan, J.M., Parikh, O., Protheroe, A., Rudman, S., Srihari, N.N., Simms, M., Tanguay, J.S., Tolan, S., Wagstaff, J., Wallace, J., Wylie, J., Zarkar, A., Sydes, M.R., Parmar, M.K.B., James, N.D.

“…STAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naïve prostate cancer patients…”
Get full text

When no treatment is the best treatment: Active surveillance strategies for low risk prostate cancers by Stavrinides, V, Parker, C.C, Moore, C.M

“…Highlights • Active surveillance is a standard approach for managing low grade, organ-confined prostate cancers. • Careful selection and close monitoring of…”
Get full text

19LBA Docetaxel (Doc) +/− zoledronic acid (ZA) for hormone-naive prostate cancer: First overall survival results from STAMPEDE & treatment effects within subgroups (NCT00268476) by James, N.D, Sydes, M.R, Mason, M.D, Clarke, N.W, Dearnaley, D.P, Spears, M.R, Millman, R, Parker, C.C, Ritchie, A.W.S, Russell, J.M, Staffurth, J, Jones, R.J, Cathomas, R, Robinson, A, Chowdhury, S, Tsang, D, Brock, S, Parikh, O, Graham, J.D, Parmar, M.K.B

Get full text

Impact of Node Status and Radiotherapy on Failure-Free Survival in Patients With Newly–Diagnosed Non-Metastatic Prostate Cancer: Data From >690 Patients in the Control Arm of the STAMPEDE Trial by James, N.D, Spears, M.R, Clarke, N.W, Sydes, M.R, Parker, C.C, Dearnaley, D.P, Russell, J.M, Ritchie, A.W.S, Thalmann, G, De Bono, J.S, Attard, G, Amos, C, Parmar, M.K, Mason, M.D

Get full text

Prostate Radiotherapy for Men with Metastatic Disease: A New Comparison in the STAMPEDE Trial by Parker, C.C, Sydes, M.R, Mason, M.D, Clarke, N.W, Aebersold, D, de Bono, J.S, Dearnaley, D.P, Ritchie, A.W.S, Russell, J.M, Thalmann, G, Parmar, M.K.B, James, N.D

Get full text

Frequency of Screening Magnetic Resonance Imaging to Detect Occult Spinal Cord Compromise and to Prevent Neurological Deficit in Metastatic Castration-resistant Prostate Cancer by Venkitaraman, R, Sohaib, S.A, Barbachano, Y, Parker, C.C, Huddart, R.A, Horwich, A, Dearnaley, D

“…Abstract Aims Neurological deficit from malignant spinal cord compression (SCC) is a major complication of metastatic castration-resistant prostate cancer…”
Get full text

Breast Conservation Therapy Is a Viable Option for Patients with Triple-Receptor Negative Breast Cancer by Parker, C.C, Smith, M.H, Henderson, A.E, Li, B.D, Ampil, F, Chu, Q.D

Get full text

Detection of Occult Spinal Cord Compression with Magnetic Resonance Imaging of the Spine by Venkitaraman, R, Sohaib, S.A, Barbachano, Y, Parker, C.C, Khoo, V, Huddart, R.A, Horwich, A, Dearnaley, D.P

“…Abstract Aims Spinal cord compression (SCC) is the most significant complication due to skeletal metastasis from prostate cancer. The early detection of SCC is…”
Get full text

Does Magnetic Resonance Imaging of the Spine Have a Role in the Staging of Prostate Cancer? by Venkitaraman, R, Cook, G.J.R, Dearnaley, D.P, Parker, C.C, Huddart, R.A, Khoo, V, Eeles, R, Horwich, A, Sohaib, S.A

“…Abstract Aims Magnetic resonance imaging (MRI) is an effective method for evaluating the spine in patients with a high risk of metastatic disease. The aim of…”
Get full text

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol by Sydes, M.R., Spears, M.R., Mason, M.D., Clarke, N.W., Dearnaley, D.P., de Bono, J.S., Attard, G., Chowdhury, S., Cross, W., Gillessen, S., Malik, Z.I., Jones, R., Parker, C.C., Ritchie, A.W.S., Russell, J.M., Millman, R., Matheson, D., Amos, C., Gilson, C., Birtle, A., Brock, S., Capaldi, L., Chakraborti, P., Choudhury, A., Evans, L., Ford, D., Gale, J., Gibbs, S., Gilbert, D.C., Hughes, R., McLaren, D., Lester, J.F., Nikapota, A., O’Sullivan, J., Parikh, O., Peedell, C., Protheroe, A., Rudman, S.M., Shaffer, R., Sheehan, D., Simms, M., Srihari, N., Strebel, R., Sundar, S., Tolan, S., Tsang, D., Varughese, M., Wagstaff, J., Parmar, M.K.B., James, N.D.

“…Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care (SOC) each improved survival in systemic therapy…”
Get full text

2018 Benefit of radiotherapy dose escalation in localized prostate cancer with respect to expression of intrinsic markers of hypoxia by McVey, G.P, Morgan, S.C, Vergis, R, Cooper, C, Huddart, R, Corbishley, C, Horwich, A, Dearnaley, D.P, Parker, C.C

Get full text

Reply to 'Letter to the Editor regarding "Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial [NCT00541047]", by C. C. Parker et al.' by Parker, C C, Catton, C N, Clarke, N, Meidahl, P, Parmar, M, Parulekar, W, Sydes, M

Get more information

Viable Eimeria oocysts in poultry house litter at the time of chick placement by Jenkins, M C, Parker, C C, O'Brien, C N, Ritter, D

“…The purpose of this study was to determine if Eimeria oocysts recovered from litter at the time of chick placement in commercial broiler houses contained…”
Get full text

LBA64 Duration of androgen suppression with post-operative radiotherapy (DADSPORT): A collaborative meta-analysis of aggregate data by Burdett, S., Fisher, D., Parker, C.C., Sydes, M.R., Pommier, P., Sargos, P., Spratt, D.E., Kishan, A.U., Brihoum, M., Catton, C., Chabaud, S., Clarke, N., Cook, A., Latorzeff, I., Tierney, J., Vale, C.

Get full text

LBA9 Duration of androgen deprivation therapy (ADT) with post-operative radiotherapy (RT) for prostate cancer: First results of the RADICALS-HD trial (ISRCTN40814031) by Parker, C.C., Clarke, N., Cook, A., Catton, C., Cross, W.R., Kynaston, H., Logue, J., Petersen, P.M., Neville, P., Persad, R., Payne, H., Saad, F., Stirling, A., Parulekar, W.R., Parmar, M.K., Sydes, M.R.

Get full text

4004 ORAL Avoiding overtreatment of prostate cancer: optimising patient selection for active surveillance by van As, N, Norman, A.R, Khoo, V.S, Thompson, A, Huddart, R.A, Horwich, A, Dearnaley, D.P, Parker, C.C

Get full text

Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047) by Parker, C C, Petersen, P M, Cook, A D, Clarke, N W, Catton, C, Cross, W R, Kynaston, H, Parulekar, W R, Persad, R A, Saad, F, Bower, L, Durkan, G C, Logue, J, Maniatis, C, Noor, D, Payne, H, Anderson, J, Bahl, A K, Bashir, F, Bottomley, D M, Brasso, K, Capaldi, L, Chung, C, Cooke, P W, Donohue, J F, Eddy, B, Heath, C M, Henderson, A, Henry, A, Jaganathan, R, Jakobsen, H, James, N D, Joseph, J, Lees, K, Lester, J, Lindberg, H, Makar, A, Morris, S L, Oommen, N, Ostler, P, Owen, L, Patel, P, Pope, A, Popert, R, Raman, R, Ramani, V, Røder, A, Sayers, I, Simms, M, Srinivasan, V, Sundaram, S, Tarver, K L, Tran, A, Wells, P, Wilson, J, Zarkar, A M, Parmar, M K B, Sydes, M R

“…The optimal timing of radiotherapy (RT) after radical prostatectomy for prostate cancer has been uncertain. RADICALS-RT compared efficacy and safety of…”
Get more information

RADICALS-HD: Reflections before the Results are Known by Parker, C C, Clarke, N W, Catton, C, Kynaston, H, Cook, A, Cross, W, Davidson, C, Goldstein, C, Logue, J, Maniatis, C, Petersen, P M, Neville, P, Payne, H, Persad, R, Pugh, C, Stirling, A, Saad, F, Parulekar, W R, Parmar, M K B, Sydes, M R

Get full text

Effects of abiraterone acetate plus prednisone/prednisolone in high and low risk metastatic hormone sensitive prostate cancer by Hoyle, A.P., Ali, S.A., James, N.D., Parker, C.C., Cook, A.D., Attard, G., Chowdhury, S., Cross, W., Dearnaley, D.P., de Bono, J.S., Gilson, C.E., Gillessen, S., Jones, R., Matheson, D., Mason, M.D., Ritchie, A., Russell, M., Parmar, M.K., Sydes, M.R., Clarke, N.W.

Get full text

Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial by Clarke, N.W., Ali, A., Ingleby, F.C., Hoyle, A., Amos, C.L., Attard, G., Brawley, C.D., Calvert, J., Chowdhury, S., Cook, A., Cross, W., Dearnaley, D.P., Douis, H., Gilbert, D., Gillessen, S., Jones, R.J., Langley, R.E., MacNair, A., Malik, Z., Mason, M.D., Matheson, D., Millman, R., Parker, C.C., Ritchie, A.W.S., Rush, H., Russell, J.M., Brown, J., Beesley, S., Birtle, A., Capaldi, L., Gale, J., Gibbs, S., Lydon, A., Nikapota, A., Omlin, A., O’Sullivan, J.M., Parikh, O., Protheroe, A., Rudman, S., Srihari, N.N., Simms, M., Tanguay, J.S., Tolan, S., Wagstaff, J., Wallace, J., Wylie, J., Zarkar, A., Sydes, M.R., Parmar, M.K.B., James, N.D.

Get full text